Screening approaches to cardiac amyloidosis in different clinical settings: Current practice and future perspectives
暂无分享,去创建一个
P. Cortelli | O. Leone | C. Gagliardi | S. Longhi | E. Biagini | N. Galiè | P. Guaraldi | V. Parisi | A. Caponetti | R. Ditaranto | G. Saturi | A. Ponziani | P. Massa | A. Accietto | M. Sguazzotti | A. Giovannetti
[1] J. Bogaert,et al. Role of cardiovascular magnetic resonance in the clinical evaluation of left ventricular hypertrophy: a 360° panorama , 2022, The International Journal of Cardiovascular Imaging.
[2] N. Kelekis,et al. Diagnostic and Prognostic Value of non-LGE Cardiac Magnetic Resonance Parameters in Cardiac Amyloidosis. , 2022, Current problems in cardiology.
[3] R. Santi,et al. Transthyretin Cardiac Amyloidosis: A Cardio-Orthopedic Disease , 2022, Biomedicines.
[4] M. Maurer,et al. Screening for Cardiac Amyloidosis 5 to 15 Years After Surgery for Bilateral Carpal Tunnel Syndrome. , 2022, Journal of the American College of Cardiology.
[5] D. Iakovidis,et al. Artificial Intelligence in Cardiology—A Narrative Review of Current Status , 2022, Journal of clinical medicine.
[6] Sawsan S. Al-Haroon,et al. Amyloid Deposits in the Ligamentum Flavum Related to Lumbar Spinal Canal Stenosis and Lumbar Disc Degeneration , 2022, Cureus.
[7] L. Køber,et al. Carpal Tunnel Syndrome in Patients Who Underwent Pacemaker Implantation and Relation to Amyloidosis, Heart Failure, and Mortality. , 2022, The American journal of cardiology.
[8] C. Autore,et al. Incidence and risk factors for pacemaker implantation in light‐chain and transthyretin cardiac amyloidosis , 2022, European journal of heart failure.
[9] M. Emdin,et al. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta‐analysis of screening studies , 2022, European journal of heart failure.
[10] C. Autore,et al. Prevalence and prognostic role of nonsustained ventricular tachycardia in cardiac amyloidosis , 2022, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[11] G. Parati,et al. Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC‐TIVE study, an Italian nationwide survey , 2022, European journal of heart failure.
[12] K. Ananthasubramaniam,et al. Epidemiology and clinical manifestations of cardiac amyloidosis , 2021, Heart Failure Reviews.
[13] O. Wazni,et al. Electrophysiological Manifestations of Cardiac Amyloidosis , 2021, JACC. CardioOncology.
[14] C. Rapezzi,et al. Transthyretin amyloidosis in aortic stenosis: clinical and therapeutic implications , 2021, European heart journal supplements : journal of the European Society of Cardiology.
[15] Dennis H. Murphree,et al. Artificial Intelligence-Enhanced Electrocardiogram for the Early Detection of Cardiac Amyloidosis. , 2021, Mayo Clinic proceedings.
[16] U. Eriksson,et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases , 2021, European journal of heart failure.
[17] A. Mayr,et al. Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement , 2020, Wiener klinische Wochenschrift.
[18] P. Lindqvist,et al. Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic , 2020, ESC heart failure.
[19] C. Rapezzi,et al. Aortic stenosis, transcatheter aortic valve replacement and transthyretin cardiac amyloidosis: are we progressively unraveling the tangle? , 2020, European journal of heart failure.
[20] J. Moon,et al. Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis , 2020, Journal of the American College of Cardiology.
[21] E. Velazquez,et al. Heart Failure With Preserved Ejection Fraction: Time for a Reset. , 2020, JAMA.
[22] E. Klotz,et al. Identifying Cardiac Amyloid in Aortic Stenosis , 2020, JACC. Cardiovascular imaging.
[23] M. Emdin,et al. [18F]-Florbetaben PET/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions. , 2020, JACC. Cardiovascular imaging.
[24] W. Saliba,et al. Prevalence, Incidence, and Impact on Mortality of Conduction System Disease in Transthyretin Cardiac Amyloidosis. , 2020, The American journal of cardiology.
[25] B. Goodwin,et al. Estimation of prevalence of transthyretin (ATTR) cardiac amyloidosis in an Australian subpopulation using bone scans with echocardiography and clinical correlation , 2020, Journal of Nuclear Cardiology.
[26] G. Niccoli,et al. Heart failure with preserved ejection fraction diagnosis and treatment: An updated review of the evidence. , 2020, Progress in cardiovascular diseases.
[27] D. Darden,et al. Management of Arrhythmias in Cardiac Amyloidosis. , 2020, JACC. Clinical electrophysiology.
[28] A. Masri,et al. Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis , 2020, European journal of heart failure.
[29] C. Di Mario,et al. Baseline ECG Features and Arrhythmic Profile in Transthyretin Versus Light Chain Cardiac Amyloidosis. , 2020, Circulation. Heart failure.
[30] A. Farioli,et al. Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies , 2020, European journal of heart failure.
[31] G. Parati,et al. Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. , 2020, International journal of cardiology.
[32] G. Pontone,et al. Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis. , 2019, JACC. Cardiovascular imaging.
[33] P. Hawkins,et al. Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria , 2019, Haematologica.
[34] L. Køber,et al. Association of Carpal Tunnel Syndrome With Amyloidosis, Heart Failure, and Adverse Cardiovascular Outcomes. , 2019, Journal of the American College of Cardiology.
[35] R. Nkoulou,et al. Amyloid PET imaging in cardiac amyloidosis: a pilot study using 18F-flutemetamol positron emission tomography , 2019, Annals of Nuclear Medicine.
[36] P. García-Pavía,et al. Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. , 2018, International journal of cardiology.
[37] D. Phelan,et al. Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. , 2018, Journal of the American College of Cardiology.
[38] Philip A. Gable,et al. On the role of asymmetric frontal cortical activity in approach and withdrawal motivation: An updated review of the evidence. , 2018, Psychophysiology.
[39] M. Maurer,et al. Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier? , 2017, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[40] R. Falk,et al. Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis , 2017, JAMA.
[41] P. Elliott,et al. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis , 2017, Circulation.
[42] D. Chemla,et al. Cardiac Dysautonomia Predicts Long-Term Survival in Hereditary Transthyretin Amyloidosis After Liver Transplantation. , 2016, JACC. Cardiovascular imaging.
[43] S. K. White,et al. Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement. , 2016, Circulation. Cardiovascular imaging.
[44] William Y S Wang,et al. Cardiac Amyloid Imaging with 18F-Florbetaben PET: A Pilot Study , 2016, The Journal of Nuclear Medicine.
[45] H. Rousseau,et al. Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy , 2016, The International Journal of Cardiovascular Imaging.
[46] C. Rapezzi,et al. Coexistence of Degenerative Aortic Stenosis and Wild-Type Transthyretin-Related Cardiac Amyloidosis. , 2016, JACC. Cardiovascular imaging.
[47] R. Falk,et al. Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy. , 2016, Heart rhythm.
[48] A. Dispenzieri,et al. Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy , 2016, Acta Haematologica.
[49] E. González-López,et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.
[50] F. Salvi,et al. Cardiac amyloidosis: the great pretender , 2015, Heart Failure Reviews.
[51] J. Cavenagh,et al. Guidelines on the diagnosis and investigation of AL amyloidosis , 2015, British journal of haematology.
[52] A. Dispenzieri,et al. Natural history and therapy of AL cardiac amyloidosis , 2015, Heart Failure Reviews.
[53] F. Salvi,et al. Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. , 2014, JACC. Cardiovascular imaging.
[54] W. Edwards,et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. , 2014, JACC. Heart failure.
[55] James D. Thomas,et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis , 2012, Heart.
[56] H. Jono,et al. Wild-type transthyretin-derived amyloidosis in various ligaments and tendons. , 2011, Human pathology.
[57] J. Kelly,et al. Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. , 2011, Biochemical and biophysical research communications.
[58] F. Salvi,et al. Systemic Cardiac Amyloidoses: Disease Profiles and Clinical Courses of the 3 Main Types , 2009, Circulation.
[59] C. Baird,et al. The pilot study. , 2000, Orthopedic nursing.
[60] J. Potokar. The Great Pretender , 1992, West of England medical journal.
[61] G. Hutchins,et al. The conduction system in cardiac amyloidosis. Clinical and pathologic features of 23 patients. , 1977, The American journal of medicine.